http://www.unboundmedicine.com/medline/ebm/research/tolterodineUnbound MEDLINE is a service provided by Unbound Medicine, Inc. that includes data and services from the U.S. National Library of Medicine's MEDLINE® and PubMed® databases.en-usUnbound Medicine, Inc.http://www.unboundmedicine.com/medline/ebm/record/19922546/full_citation/Cardiovascular_morbidity_heart_rates_and_use_of_antimuscarinics_in_patients_with_overactive_bladder_Andersson KE, Sarawate C, Kahler KH, et al. 
Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladder. [JOURNAL ARTICLE]
BJU Int 2009 Nov 17.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19920160/full_citation/Fesoterodine_for_the_Treatment_of_Overactive_Bladder__December___CE__Tzefos M, Dolder C, Olin JL 
Fesoterodine for the Treatment of Overactive Bladder (December) (CE). [JOURNAL ARTICLE]
Ann Pharmacother 2009 Nov 17.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19918340/full_citation/Male_urinary_incontinence:_prevalence_risk_factors_and_preventive_interventions_Shamliyan TA, Wyman JF, Ping R, et al. 
Male urinary incontinence: prevalence, risk factors, and preventive interventions. [Journal Article]
Rev Urol 2009; 11(3):145-65.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19915829/full_citation/The_pharmacokinetic_profile_of_fesoterodine_8_mg_with_daytime_or_nighttime_dosing_Malhotra BK, Crownover PH, Labadie R, et al. 
The pharmacokinetic profile of fesoterodine 8 mg with daytime or nighttime dosing. [JOURNAL ARTICLE]
Eur J Clin Pharmacol 2009 Nov 14.
Abstract | Full Citationhttp://www.unboundmedicine.com/medline/ebm/record/19913821/full_citation/Long_Term_Durability_of_Percutaneous_Tibial_Nerve_Stimulation_for_the_Treatment_of_Overactive_Bladder_Macdiarmid SA, Peters KM, Shobeiri SA, et al. 
Long-Term Durability of Percutaneous Tibial Nerve Stimulation for the Treatment of Overactive Bladder. [JOURNAL ARTICLE]
J Urol 2009 Nov 12.
Abstract | Full Citation | Publisher Full Text | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19912207/full_citation/Effect_of_fluid_management_on_fluid_intake_and_urge_incontinence_in_a_trial_for_overactive_bladder_in_women_Zimmern P, Litman HJ, Mueller E, et al. 
Effect of fluid management on fluid intake and urge incontinence in a trial for overactive bladder in women. [JOURNAL ARTICLE]
BJU Int 2009 Nov 13.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19888972/full_citation/Urodynamic_evaluation_of_fesoterodine_metabolite_doxazosin_and_their_combination_in_a_rat_model_of_partial_urethral_obstruction_Füllhase C, Soler R, Gratzke C, et al. 
Urodynamic evaluation of fesoterodine metabolite, doxazosin and their combination in a rat model of partial urethral obstruction. [JOURNAL ARTICLE]
BJU Int 2009 Nov 3.
Abstract | Full Citationhttp://www.unboundmedicine.com/medline/ebm/record/19877705/full_citation/Asymmetric_Conjugate_Reductions_of_Coumarins__A_New_Route_to_Tolterodine_and_Related_Coumarin_Derivatives_Gallagher BD, Taft BR, Lipshutz BH 
Asymmetric Conjugate Reductions of Coumarins. A New Route to Tolterodine and Related Coumarin Derivatives. [JOURNAL ARTICLE]
Org Lett 2009 Oct 30.
Abstract | Full Citation | Publisher Full Texthttp://www.unboundmedicine.com/medline/ebm/record/19875964/full_citation/Antimuscarinics_in_men_with_lower_urinary_tract_symptoms_suggestive_of_bladder_outlet_obstruction_due_to_benign_prostatic_hyperplasia_Chapple C 
Antimuscarinics in men with lower urinary tract symptoms suggestive of bladder outlet obstruction due to benign prostatic hyperplasia. [JOURNAL ARTICLE]
Curr Opin Urol 2009 Oct 28.
Abstract | Full Citationhttp://www.unboundmedicine.com/medline/ebm/record/19835561/full_citation/The_Design_and_Development_of_Fesoterodine_as_a_Prodrug_of_5_hydroxymethyl_Tolterodine__5_HMT__the_Active_Metabolite_of_Tolterodine_Malhotra B, Gandelman K, Sachse R, et al. 
The Design and Development of Fesoterodine as a Prodrug of 5-hydroxymethyl Tolterodine (5-HMT), the Active Metabolite of Tolterodine. [JOURNAL ARTICLE]
Curr Med Chem 2009 Oct 15.
Abstract | Full Citation | Find Related Articles